Antitumor effects of immunotherapy combined with BRAF and MEK inhibitors in BRAF V600E metastatic colorectal cancer

Abstract BRAF-mutated colorectal cancer correlates with poor prognosis and limited response to standard treatments. Combining immune checkpoint inhibitors with BRAF/MEK inhibitors shows promise against BRAF-mutant melanoma in both preclinical and clinical trials. Therefore, we hypothesized that the...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Cancer Immunology, Immunotherapy
المؤلفون الرئيسيون: Eunyoung Tak, Hye-In An, Amy Sinyoung Lee, Kyuyoung Han, Jiwan Choi, Hyung-don Kim, Yong Sang Hong, Sun Young Kim, Eun Kyung Choi, Jeong Eun Kim, Tae Won Kim
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Springer 2025-03-01
الموضوعات:
BRAF V600E
BRAF inhibitor
MEK inhibitor
Anti-PD-L1
Immunotherapy
الوصول للمادة أونلاين:https://doi.org/10.1007/s00262-025-04005-3

الانترنت

https://doi.org/10.1007/s00262-025-04005-3

مواد مشابهة